摘要
目的探讨文拉法辛联合度洛西汀治疗老年躯体形式疼痛障碍的临床疗效,以及对患者疼痛程度的影响。方法选取医院2018年2月至2020年2月收治的患者148例,按双色球法随机分为对照组和联合组,各74例。两组患者均口服盐酸文拉法辛缓释片,联合组患者加服盐酸度洛西汀肠溶胶囊,均连续治疗4周。结果联合组总有效率为97.30%,显著高于对照组的82.43%(P <0.05);治疗1,2,4周后,联合组患者的视觉模拟评分、汉密尔顿抑郁量表评分均显著低于对照组(P <0.05);联合组患者治疗后的5-羟色胺及去甲肾上腺素水平显著高于对照组(P <0.05);联合组与对照组的不良反应发生率相当(4.05%比6.77%,P> 0.05)。结论文拉法辛联合度洛西汀治疗老年躯体形式疼痛障碍,可明显减轻疼痛程度,改善抑郁程度,升高5-羟色胺及去甲肾上腺素水平。
Objective To investigate the clinical efficacy of venlafaxine combined with duloxetine in the treatment of elderly patients with somatoform pain disorder.Methods A total of 148 elderly patients with somatoform pain disorder admitted to our hospital from February 2018 to February 2020 were selected and randomly divided into the control group and the combined group according to the two-color ball method,74 cases in each group.The patients in the two groups were treated with Venlafaxine Hydrochloride Sustained-Release Tablets,on this basis,the patients in the combined group were treated with Duloxetine Hydrochloride Enteric-Coated Capsules.Both groups were continuously treated for four weeks.Results The total effective rate of the combined group was 97.30%,which was significantly higher than 82.43%of the control group(P<0.05).After one,two and four weeks of treatment,the scores of the visual analogue scale(VAS)and the Hamilton Depression Scale(HAMD)in the combined group were significantly lower than those in the control group(P<0.05).After treatment,the level of 5-hydroxytryptamine(5-HT)and noradrenaline(NE)in the combined group was significantly higher than that in the control group(P<0.05).The incidence of adverse reactions in the combined group was similar to that in the control group(4.05%vs.6.77%,P>0.05).Conclusion Venlafaxine combined with duloxetine in the treatment of elderly patients with somatoform pain disorder can significantly reduce the degree of pain,improve the degree of depression,increase the level of 5-HT and NE.
作者
王晓环
马占平
栗建辉
翟向男
WANG Xiaohuan;MA Zhanping;LI Jianhui;ZHAI Xiangnan(Hengshui Mental Hospital,Hengshui,Hebei,China 053800)
出处
《中国药业》
CAS
2021年第8期26-28,共3页
China Pharmaceuticals
基金
河北省中医药管理局科研计划项目[2020541]。
